Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15
Introduction
Varicella zoster virus (VZV) causes two distinct diseases. Varicella (chickenpox) is the primary infection and herpes zoster (HZ) or shingles is a reactivation of VZV which occurs due to a decline in cell mediated immunity. Shingles is a painful clinical condition characterised by a unilateral vesicular rash which can occur anywhere on the body but most commonly occurs on the trunk [1]. Post herpetic neuralgia (PHN) is the most frequent complication of shingles which causes persistent neuropathic pain. This debilitating condition extends beyond the resolution of rash, between three and six months on average and is known to contribute significantly to the overall burden of shingles within the population [2], [3], [4].
Shingles incidence in the UK has been estimated at 5.23/1000 person years based on primary care consultations [3], with a lifetime risk estimated between 25% and 35% [5], [6], [7]. Studies have reported between 2.6% and 67.3% of shingles cases develop PHN [8]. Factors that increase risk of both shingles and PHN include increasing age, female gender and immunosuppression either due to treatment or underlying conditions such as HIV and malignancy [2], [3], [9], [10], [11].
In September 2013, following a recommendation from the Joint Committee on Vaccination and Immunisation [12], [13] the UK introduced a shingles vaccination programme to individuals aged 70 years old, with a phased catch-up programme for those aged 71–79 years. The programme is delivered in general practice and operates between September and August each year. Patients are eligible throughout the year, although many receive it at the same time as their annual influenza vaccine. The aim of the vaccination programme is to reduce the incidence and severity of shingles in those targeted by the programme by boosting individuals’ pre-existing VZV immunity through vaccination with a single dose of a live attenuated vaccine (Zostavax).
In the first year of the programme (2013/14), overall coverage in England for the routine cohort was 61.8% [14]. Whilst this demonstrates effective implementation of the programme, equitable delivery, a key requirement of the national immunisation programme outlined in the NHS Public Health Functions Agreement (Section 7A) [15] under the Equality Act, 2010, had not been assessed [16].
Variation in shingles vaccine coverage by ethnicity, age and gender is documented in other high-income countries [17], [18]. Such variation has been attributed to differences in service factors (such as access and utilisation of healthcare and recommendation by the GP or midwife), individual factors (such as knowledge, attitudes and practice with respect to immunisation), sociodemographic factors (such as educational attainment and household income) and other factors including rurality.
In the UK, a number of studies have explored variation in vaccine coverage for other national vaccination programmes including childhood programmes, seasonal influenza and maternal programmes [19], [20], [21], [22], [23], [24], [25], [26], [27], [28]. Although routine shingles coverage data suggest differential coverage among different ethnic groups [14], no similar studies have been undertaken for the shingles immunisation programme in England, and the extent to which differential coverage by ethnicity is due to other, confounding factors such as deprivation or geography, is unknown.
The aims of this study are to:
- •
Assess the variation in shingles vaccine coverage across England in 70 year-olds in 2014/15 by key individual and population level factors – ethnicity, deprivation and geography.
- •
Identify predictors of shingles vaccine coverage to ascertain if inequalities persist after adjusting for other factors.
Section snippets
Data collection
Eligible and vaccinated 70 year-olds between 1 September 2014 and 31 August 2015 were extracted from GP records. The dataset was generated through the automated upload of aggregated GP practice level shingles vaccine coverage data to ImmForm, a system used by Public Health England (PHE) to monitor vaccine coverage data for new vaccine programmes and programmes targeting those over five years old [29]. ImmForm captures data from approximately 95% of GP practices in England. Eligible individuals
Participation
Of 7802 GP practices in England, shingles coverage data were available for 7473 (95.8%) practices with 502,058 registered patients for the period 1 September 2014 to 31 August 2015. Of these, 262,667 (52.3%) patients were registered at 3977 GP practices where the information system was able to provide ethnicity; 178,808 (35.6%) had ethnicity recorded and 83,859 (16.7%) had unknown ethnicity (i.e. recorded as ‘not stated’, ‘not recorded’ or ‘not given’).
Sample representativeness and overall coverage
The GP practices providing ethnicity were
Main findings
When compared to the White-British group, shingles vaccine coverage was lower in all other ethnic groups and for most of these groups, differences in coverage persisted after adjusting for IMD and LT. Coverage differences by ethnic group have also been reported for other immunisation programmes in England with studies for childhood influenza, HPV and rotavirus immunisation also reporting lower vaccine coverage in non-white ethnic groups [21], [23], [28]. In contrast, a study looking
Conclusions
This study has demonstrated that it is possible to monitor shingles vaccine coverage by ethnic group and identify groups with low recorded coverage using aggregated, routinely collected GP practice data. To strengthen our ability to use routine data to inform public health action and reduce inequalities, we recommend improved recording of coverage and sociodemographic data in GP IT systems. This will help in the delivery of equitable vaccination programmes, as mandated by the Equalities Act [16]
Funding
This work was conducted as part of routine activities at the department of Immunisation, Hepatitis and Blood Safety, Public Health England and received no specific funding.
Conflicts of interest
None.
Contributions
CW, ME and LB were involved in the conception and design of the study. CW, ME, LB and JW were involved in the acquisition of data. All authors made substantial contribution to the interpretation of data, critically revising the article for important intellectual content and final approval of the version to be submitted.
Acknowledgements
The authors would like to acknowledge all staff in PHE and NHS England responsible for the planning and delivery of the shingles immunisation programme. We thank the ImmForm team for their management of the GP sentinel data collections.
References (46)
Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
BMC Infect Dis
(2014)Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales
Vaccine
(2009)Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
Epidemiol Infect
(2009)A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
N Engl J Med
(2005)The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population
Eur J Pain
(1999)Modelling the impact of immunization on the epidemiology of varicella zoster virus
Epidemiol Infect
(2000)- et al.
Epidemiology, outcome and control of varicella-zoster infection
Rev Med Microbiol
(1993) A systematic review and meta-analysis of risk factors for postherpetic neuralgia
Pain
(2016)Risk factors for postherpetic neuralgia in patients with herpes zoster
Neurology
(2004)Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease
Jama
(2011)
Statement on varicella and herpes zoster vaccines
Trends and disparity in zoster vaccine uptake in a managed care population
Vaccine
Herpes zoster vaccine (HZV): utilization and coverage 2009–2013, Alberta, Canada
BMC Public Health
Inequalities in immunisation and breast feeding in an ethnically diverse urban area: cross-sectional study in Manchester, UK
J Epidemiol Community Health
Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: development and validation of an evidence-based measurement instrument
Vaccine
Phased introduction of a universal childhood influenza vaccination programme in England: population-level factors predicting variation in national uptake during the first year, 2013/14
Vaccine
Childhood vaccination coverage by ethnicity within London between 2006/2007 and 2010/2011
Arch Dis Child
Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services
Sex Transm Infect
Cited by (17)
Social determinants of health and vaccine uptake during the first wave of the COVID-19 pandemic: A systematic review
2023, Preventive Medicine ReportsOlder adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake
2021, VaccineCitation Excerpt :In the current study, we not only considered influenza and pneumococcal vaccine uptake in the same sample, but also that of the shingles vaccine, which has been investigated to a much lesser extent [4]. Socio-demographic factors have been shown to predict, but not wholly account for, shingles vaccination coverage (i.e. geographical area, level of deprivation, and ethnicity [43]. Although, again, healthcare providers may have a crucial role in shingles vaccine uptake, as key predictors of uptake appear to be awareness of the vaccine and having been offered and recommended it by a healthcare provider [4,24].
Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program
2020, VaccineCitation Excerpt :This pattern has also been observed in the AIR report [10] and for pneumococcal vaccine uptake [24]. We also found patients living in the most socio-economically disadvantaged areas were less likely to receive HZ vaccines; this has been previously reported in the UK [28] and the USA [26]. HZ vaccines have been introduced in other countries, including the US and the UK.
Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study
2018, The Lancet Public HealthCitation Excerpt :Cumulative uptake data indicate most vaccines were delivered during the influenza season, although the vaccine is offered opportunistically throughout the year. Uptake in the participating practices showed geographical variation, similar to that observed nationally, with ethnicity and deprivation identified as contributing factors.14 Uptake was lower than for seasonal influenza vaccination in adults aged 65 years and older, at 73·2% for the 2013–14 season, 72·7% for the 2014–15 season, and 71·0% for the 2015–16 season.15
Extracting general practice data for timely vaccine coverage estimates: The England experience
2017, VaccineCitation Excerpt :Extraction details are available in the data specifications [11]. ImmForm also allows stratification of vaccine coverage by any variable recorded, such as age (by date of birth), ethnicity, gender, specific co-morbidities (e.g. chronic heart disease, diabetes) [12] and place of administration (practice, school, pharmacy etc). The specifications and outputs are internally and externally validated and quality assured to ensure the coverage reported is accurate.
Forecasting sub-national trends in COVID-19 vaccine uptake in the UK before vaccine rollout
2022, Scientific Reports